| Dr Gregory Jon Simpson, OD | |
|
1800 Hway 95, Bullhead City, AZ 86442 | |
| (928) 763-8443 | |
| (928) 763-3073 |
| Full Name | Dr Gregory Jon Simpson |
|---|---|
| Gender | Male |
| Speciality | Optometry |
| Experience | 19 Years |
| Location | 1800 Hway 95, Bullhead City, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1912922378 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 1542 (Arizona) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Western Medical Eye Center Llc | 4284721549 | 3 |
News Archive
Although tonsillectomy is therapeutic for chronic tonsillitis, the procedure has the potential to affect speech quality, by altering the resonant characteristics of the vocal tract, and to modify velopharyngeal function (the closing off of the nose from the mouth during speech).
The U.S. Food and Drug Administration (FDA) has issued a public health advisory outlining new safety information, including revised product labeling about erythropoiesis-stimulating agents (ESAs), widely-used drugs for the treatment of anemia.
The current issue of the Department of Veterans Affairs (VA's) Journal of Rehabilitation Research and Development (JRRD) features 19 timely scientific articles on traumatic brain injury (TBI), based on work by VA researchers and colleagues from a variety of disciplines. The papers were commissioned for a "state of the art" conference VA held last year to advance research in this area.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that on Thursday, January 20, 2011, it submitted a Post Approval Supplement containing data supporting the removal of the Indium-111 ZEVALIN® pre-treatment imaging evaluation, more commonly referred to as the "bioscan" requirement.
Seattle Genetics, Inc. announced today that it has achieved a milestone under its antibody-drug conjugate (ADC) collaboration with Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc. The milestone was triggered by Agensys' initiation of a phase I trial for AGS-16M8F, an ADC for the treatment of cancer utilizing Seattle Genetics' technology.
› Verified 2 days ago
| Provider Name | Western Medical Eye Center Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1760664825 PECOS PAC ID: 4284721549 Enrollment ID: O20071102000221 |
News Archive
Although tonsillectomy is therapeutic for chronic tonsillitis, the procedure has the potential to affect speech quality, by altering the resonant characteristics of the vocal tract, and to modify velopharyngeal function (the closing off of the nose from the mouth during speech).
The U.S. Food and Drug Administration (FDA) has issued a public health advisory outlining new safety information, including revised product labeling about erythropoiesis-stimulating agents (ESAs), widely-used drugs for the treatment of anemia.
The current issue of the Department of Veterans Affairs (VA's) Journal of Rehabilitation Research and Development (JRRD) features 19 timely scientific articles on traumatic brain injury (TBI), based on work by VA researchers and colleagues from a variety of disciplines. The papers were commissioned for a "state of the art" conference VA held last year to advance research in this area.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that on Thursday, January 20, 2011, it submitted a Post Approval Supplement containing data supporting the removal of the Indium-111 ZEVALIN® pre-treatment imaging evaluation, more commonly referred to as the "bioscan" requirement.
Seattle Genetics, Inc. announced today that it has achieved a milestone under its antibody-drug conjugate (ADC) collaboration with Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc. The milestone was triggered by Agensys' initiation of a phase I trial for AGS-16M8F, an ADC for the treatment of cancer utilizing Seattle Genetics' technology.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Gregory Jon Simpson, OD 1800 Hway 95, Bullhead City, AZ 86442-6803 Ph: (928) 763-4333 | Dr Gregory Jon Simpson, OD 1800 Hway 95, Bullhead City, AZ 86442 Ph: (928) 763-8443 |
News Archive
Although tonsillectomy is therapeutic for chronic tonsillitis, the procedure has the potential to affect speech quality, by altering the resonant characteristics of the vocal tract, and to modify velopharyngeal function (the closing off of the nose from the mouth during speech).
The U.S. Food and Drug Administration (FDA) has issued a public health advisory outlining new safety information, including revised product labeling about erythropoiesis-stimulating agents (ESAs), widely-used drugs for the treatment of anemia.
The current issue of the Department of Veterans Affairs (VA's) Journal of Rehabilitation Research and Development (JRRD) features 19 timely scientific articles on traumatic brain injury (TBI), based on work by VA researchers and colleagues from a variety of disciplines. The papers were commissioned for a "state of the art" conference VA held last year to advance research in this area.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that on Thursday, January 20, 2011, it submitted a Post Approval Supplement containing data supporting the removal of the Indium-111 ZEVALIN® pre-treatment imaging evaluation, more commonly referred to as the "bioscan" requirement.
Seattle Genetics, Inc. announced today that it has achieved a milestone under its antibody-drug conjugate (ADC) collaboration with Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc. The milestone was triggered by Agensys' initiation of a phase I trial for AGS-16M8F, an ADC for the treatment of cancer utilizing Seattle Genetics' technology.
› Verified 2 days ago
Clark Eyecare, P.c. Optometrist Medicare: Medicare Enrolled Practice Location: 2840 Highway 95, Walmart Vision Center Suite 505, Bullhead City, AZ 86442 Phone: 928-758-1524 Fax: 928-758-1683 | |
Dr. James A. Richardson, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 2840 Hiway 95, Suite 108, Bullhead City, AZ 86442 Phone: 928-758-2020 Fax: 928-758-4544 | |
Dr. Jennifer Phuong-uyen Nguyen, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 2840 Highway 95 Ste 416-418, Bullhead City, AZ 86442 Phone: 928-704-1808 Fax: 928-704-1814 | |
Dr. Eric Brendon Jones, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 2840 Hwy. 95, Suite #108, Bullhead City, AZ 86442 Phone: 928-758-2020 Fax: 928-758-4544 | |
Mohave Eye Center, Ltd Optometrist Medicare: Not Enrolled in Medicare Practice Location: 3003 Highway 95, Suite 11, Bullhead City, AZ 86442 Phone: 928-763-1000 Fax: 928-758-4983 | |
Dr. Christopher N Clark, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 2840 Highway 95 Ste 505, Bullhead City, AZ 86442 Phone: 928-758-1450 Fax: 928-758-1683 | |
Colorado River Eye Care, Pc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 2840 Hiway 95, Suite 108, Bullhead City, AZ 86442 Phone: 958-758-2020 Fax: 928-758-4544 |